Phase I Study of Subcutaneous Ocaratuzumab in Patients With Previously Treated CD20+ B-Cell Malignancies

NCT01858181 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Previously Treated CD20+ B-cell Malignancies

Interventions

BIOLOGICAL: ocaratuzumab

Sponsor

Mentrik Biotech, LLC